Zevra Therapeutics (ZVRA) Profit After Tax (2014 - 2026)

Zevra Therapeutics has reported Profit After Tax for 13 years, with the latest figure at $37.9 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 1322.65% year-over-year to $37.9 million; the trailing twelve-month figure through Mar 2026 stood at $124.2 million (up 235.04% YoY), and the FY2025 full-year result was $83.2 million, up 178.88% from the prior year.
• Profit After Tax for Q1 2026 stood at $37.9 million, up from $12.2 million in the prior quarter.
• The five-year high for Profit After Tax was $74.7 million in Q2 2025, with the low at -$35.7 million in Q4 2024.
• Historically, Profit After Tax has averaged -$655666.7 across 5 years, with a median of -$3.1 million in 2025.
• Annual changes were most pronounced in 2024 — Profit After Tax slumped 674.39% — and 2026, when it jumped 1322.65%.
• Zevra Therapeutics' Profit After Tax stood at -$3.0 million in 2022, then sank by 128.8% to -$6.8 million in 2023, then plunged by 425.57% to -$35.7 million in 2024, then soared by 134.04% to $12.2 million in 2025, then jumped by 211.47% to $37.9 million in 2026.
• The last three Profit After Tax figures came in at $37.9 million (Q1 2026), $12.2 million (Q4 2025), and -$544000.0 (Q3 2025), per Business Quant data.